Table 1.
AZT dose (mg/kg/d) |
RBC count (106/mm3) |
Hb content (g/dL) |
MCV (μm3) |
MCH (pg) |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0-week | 11-week | 0-week | 11-week | 0-week | 11-week | 0-week | 11-week | |||||||||
Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | |
0 | 9.9 ± 0.3 |
10.1 ± 0.5 |
11.0a
± 0.1 |
11.5 ± 0.3 |
16.5 ± 0.6 |
16.9 ± 0.7 |
16.9 ± 0.5 |
18.2 ± 0.7 |
46.6 ± 0.2 |
47.0 ± 0.3 |
47.0 ± 2.0 |
48.5 ± 1.2 |
16.4 ± 0.3 |
16.6 ± 0.2 |
15.4 ± 0.5 |
15.8a
± 0.3 |
| ||||||||||||||||
400 | 8.7 ± 0.7 |
9.8 ± 0.5 |
7.6 ± 0.4 |
7.3a
± 0.3 |
14.2 ± 1.2 |
16.5 ± 0.9 |
14.4 ± 0.9 |
14.4 ± 0.8 |
47.2 ± 0.3 |
46.8 ± 0.3 |
57.8a
± 0.3 |
60.5a,b
± 0.5 |
16.5 ± 0.1 |
16.7 ± 0.2 |
19.0a
± 0.1 |
19.8a,b
± 0.2 |
| ||||||||||||||||
500 | 8.6 ± 0.7 |
10.0 ± 0.7 |
7.7 ± 0.1 |
8.4b
± 0.1 |
14.1 ± 1.2 |
16.5 ± 1.2 |
14.8 ± 0.3 |
16.5b
± 0.2 |
47.8 ± 0.3 |
46.7 ± 0.2 |
58.5a
± 0.5 |
60.3a,b
± 0.3 |
16.4 ± 0.1 |
16.4 ± 0.2 |
19.2a
± 0.1 |
19.7a,b
± 0.1 |
| ||||||||||||||||
600 | 8.6 ± 0.7 |
8.8 ± 0.3 |
7.9 ± 0.5 |
6.7a
± 1.1 |
14.1 ± 1.2 |
14.4 ± 0.4 |
15.6 ± 0.8 |
13.6 ± 2.1 |
46.6 ± 0.7 |
46.2 ± 0.6 |
60.3a
± 0.7 |
63.0a
± 1.0 |
16.2 ± 0.2 |
16.2 ± 0.1 |
19.7a
± 0.2 |
20.6a
± 0.4 |
aindicates a significant (P < 0.05) difference in hematological parameter at 11-week compared to 0-week for each sex.
bindicates a significant (P < 0.05) sex-based difference in hematological parameter in female mice compared to male counterparts at 11-week. Values are presented as the mean ± SEM (N = 4–6). Also, a significant (P < 0.05) dose-related response was noted in the RBC count, Hb content, MCV, and MCH level in both sexes.